Publications by authors named "A Fernandez-Ortega"
Article Synopsis
- The study aimed to assess the effectiveness of olaparib in patients with advanced triple negative breast cancer who have homologous recombination deficiency but do not have BRCA1/2 mutations.
- The NOBROLA trial was conducted as a phase IIa study, enrolling patients treated with olaparib, and focused on the clinical benefit rate as the main measurement.
- Out of 114 patients screened, only 6 were eligible; the median follow-up was 8.5 months, showing a clinical benefit rate of 50%, suggesting potential for further research.
Role of [18F]FDG PET/CT in the evaluation of inflammatory breast cancer: A case report.
Rev Esp Med Nucl Imagen Mol (Engl Ed)
September 2024
Article Synopsis
- Leptomeningeal disease (LMD) significantly impacts survival and quality of life, and trastuzumab deruxtecan (T-DXd) has demonstrated effectiveness in treating advanced HER2-positive and HER2-low breast cancer in patients with a history of brain metastases or LMD.
- In a phase 2 trial involving seven patients with confirmed LMD, T-DXd was administered, revealing a median overall survival (OS) of 13.3 months and a progression-free survival (PFS) of 8.9 months, with many patients achieving disease stabilization.
- The results suggest T-DXd has promising activity in this challenging patient population, indicating a need for further research on its efficacy in treating LMD.
Background: Trastuzumab deruxtecan (T-DXd) is approved for human epidermal growth factor receptor 2 (HER2)-positive and HER2-low advanced breast cancer (ABC). T-DXd has shown encouraging intracranial activity in HER2-positive ABC patients with stable or active brain metastases (BMs); however, its efficacy in patients with HER2-low ABC with BMs is not well established yet.
Methods: DEBBRAH is a single-arm, five-cohort, phase II study evaluating T-DXd in patients with central nervous system involvement from HER2-positive and HER2-low ABC.
Background: Hyperglycaemia is an early and frequent adverse event during alpelisib treatment. METALLICA aimed to evaluate prophylactic metformin to prevent or reduce hyperglycaemia occurrence in patients with HR+/HER2-/-mutated advanced breast cancer (ABC).
Methods: Between August 13th, 2020 and March 23rd, 2022, this 2-cohort, phase 2, multicentre, single-arm trial (NCT04300790) enrolled patients with HR+/HER2-/PIK3CA-mutated ABC: cohort A, normal glycaemia (fasting plasma glucose <100 mg/dL [<5.